



Special Track 1

Oncology and Theranostics Committee

Sunday, October 18, 08:00–09:30

Session Title

From Innovation to Recommendation: Introducing FAPI in Clinical Guidelines

Moderators

Helle Zacho (Aalborg, Denmark)

Antonios Tzortzakakis (Stockholm, Sweden)

Point of View: FAPI PET on Trials: Is Survival Data Essential for Clinical Adoption?

Sophie Veldhuijzen van Zanten (Rotterdam, Netherlands)

Point of View: Beyond the Hype: Are We Ready to Expand FAPI Indications in Oncology?

Wolfgang Fendler (Essen, Germany)

Educational Objectives

1. To underline the role of FAPI as an oncological PET tracer
2. To provide an overview of current literature related to FAPI PET
3. To describe the main clinical indications, but also the limitations and pitfalls of FAPI PET

Summary

FAPI PET is an emerging oncological imaging technique that targets fibroblast activation protein expressed by cancer-associated fibroblasts, allowing visualisation of the tumour microenvironment rather than tumour metabolism as in FDG PET. In this session the discussion will focus on current indications for the use of FAPI PET in oncology, as well as its major limitations (i.e., its lack of specificity), as increased uptake also occurs in benign conditions like inflammation, fibrosis, and wound healing, leading to frequent false positives. Current literature—largely based on small and heterogeneous studies—supports its diagnostic potential and emerging prognostic and theranostic roles, but emphasises the need for larger prospective trials and careful interpretation alongside clinical and other imaging findings.

Key Words

FAPI PET, Oncology, Overall Survival